mTORC1通路通过抑制SIRT4刺激谷氨胺代谢和细胞增殖
Alfred Csibi1, Sarah-Maria Fendt, Chenggang Li
1Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Cell
|May 14, 2013
概括
拉巴胺素复合物1 (mTORC1) 的哺乳动物点通过抑制SIRT4,一种关键的谷氨酸脱酶 (GDH) 调节剂,激活谷氨酸代谢. 这一途径在癌症中至关重要,建议新的治疗点.
科学领域:
- 细胞代谢的细胞代谢.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 增殖细胞利用谷氨酸进行生物合成和能量.
- 拉巴amycin复合体1 (mTORC1) 的哺乳动物点与营养代谢的增加有关.
- mTORC1和谷氨酸溶解之间的分子联系仍然不清楚.
研究的目的:
- 阐明mTORC1影响谷氨胺代谢的分子机制.
- 为了研究SIRT4在mTORC1-介导的谷氨酸溶解中的作用.
- 探索在癌症中准这种途径的治疗潜力.
主要方法:
- 研究了mTORC1激活对谷氨酸脱酶 (GDH) 活性的影响.
- 评估SIRT4在调节GDH中的作用.
- 通过CREB2.2检查了mTORC1对SIRT4表达和稳定性的影响.
- 在人类癌症组织中分析了SIRT4表达.
- 评估了SIRT4过度表达对癌细胞增殖和瘤发育的影响.
主要成果:
- 通过激活GDH,mTORC1的激活促进了谷氨胺克症.
- 这种激活是由SIRT4的转录抑制介导的,SIRT4是GDH的抑制剂.
- mTORC1会破坏CREB2的稳定,导致SIRT4的表达减少.
- 在人类癌症中,SIRT4表达减少.
- 过度表达SIRT4可以抑制癌细胞的增殖,转化和瘤生长.
结论:
- mTORC1通过SIRT4/GDH轴调节谷氨胺代谢.
- mTORC1-SIRT4通路与癌症的发展有关.
- 在mTORC1-高癌症中准营养代谢是一种潜在的治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
